P2RY12 and Thrombocytopenia: Because the present study demonstrates that clopidogrel is a good and reasonable therapeutic option with MACCE rates similar to those of potent P2Y12 inhibitors for Korean AMI patients with baseline thrombocytopenia, it fully supports the concept of the East Asian paradox, even in this clinical setting.